In this model, tauopathy was induced in older non-human primates (NHPs) through double-tau mutations introduced in entorhinal cortex bilaterally. NHPs were administered SLS-005 weekly and demonstrated a 46% reduction in tau protein and an 18% reduction in NfL neurofilament light chain (NfL) protein biomarker from baseline values over 6 months in a preliminary analysis. NfL is a non-specific biomarker for several neurodegenerative conditions, including Alzheimer's disease,
'The current results further validate SLS-005 as a potential pipeline-in-a-product by activating autophagy, a novel mechanism of action that would clear only mutant, toxic, and aggregating proteins. This has now been demonstrated in two aggressive and fast progressing neurodegenerative disease models of
Seelos will present a poster on
Title: Trehalose treatment in an AAV-tau model of Alzheimer's disease
Co-Authors:
Presenter:
About SLS-005 (trehalose injection, 90.5 mg/mL for intravenous infusion)
SLS-005 is a low molecular weight disaccharide (0.342 kDa) that crosses the blood brain barrier and is thought to stabilize proteins and activate autophagy through the activation of Transcription Factor EB (TFEB), a key factor in lysosomal and autophagy gene expression. The activation of TFEB is an emerging therapeutic target for a number of diseases with pathologic accumulation of storage material. In animal models of several diseases associated with abnormal cellular protein aggregation or storage of pathologic material, SLS-005 has been shown to reduce aggregation of misfolded proteins and reduce accumulation of pathologic material. SLS-005 is an investigational treatment and is not currently approved by any health authority for medicinal use.
About
Forward Looking Statements
Statements made in this press release, which are not historical in nature, constitute forward-looking statements for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. These statements include, among others, those regarding the safety and efficacy of SLS-005 and its ability to clear only mutant, toxic, and aggregating proteins in the body and its potential as a pipeline-in-a-product. These statements are based on Seelos' current expectations and beliefs and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Risks associated with Seelos' business include, but are not limited to, the risk of not successfully executing its preclinical and clinical studies and not gaining marketing approvals for its product candidates, the risk that prior clinical results may not be replicated in future studies and trials (including the risk that the results from the preclinical in-vivo studies of SLS-005 or non-human studies are not replicated or are materially different from the results of future studies and trials), the risks that clinical study results may not meet any or all endpoints of a clinical study and that any data generated from such studies may not support a regulatory submission or approval, the risks associated with the implementation of Seelos' business strategy, the risks related to raising capital to fund its development plans and ongoing operations, risks related to Seelos' current stock price and listing on the Nasdaq Capital Market, as well as other factors expressed in Seelos' periodic filings with the
Contact:
Tel: (646) 293-2136
Email: anthony.marciano@seelostx.com
Web: https://seelostherapeutics.com
Tel: (617) 308-4306
Email: mmoyer@lifesciadvisors.com
(C) 2023 Electronic News Publishing, source